• 1
    Thiede C,Koch S,Creutzig E, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 2006; 107: 40114020.
  • 2
    Schnittger S,Schoch C,Kern W, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005; 106: 37333739.
  • 3
    Gale RE,Green C,Allen C, et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008; 111: 27762784.
  • 4
    Döhner K,Schlenk RF,Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: Interaction with other gene mutations. Blood 2005; 106: 37403746.
  • 5
    Schlenk RF,Döhner K,Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 19091918.
  • 6
    Ghanem H,Tank N,Tabbara IA. Prognostic implications of genetic aberrations in acute myelogenous leukemia with normal cytogenetics. Am J Hematol 2012; 87: 6977.
  • 7
    Estey EH. Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012; 87: 8999.
  • 8
    Döhner H,Estey EH,Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453474.
  • 9
    Chevallier P,Fornecker L,Lioure B, et al. Tandem versus single autologous peripheral blood stem cell transplantation as post-remission therapy in adult acute myeloid leukemia patients under 60 in first complete remission: Results of the multicenter prospective phase III GOELAMS LAM-2001 trial. Leukemia 2010; 24: 13801385.
  • 10
    Lioure B,Bene MC,Pigneux A, et al. Early matched sibling hematopoietic-cell transplantation for adult AML in first remission using an age-adapted strategy: Long-term results of a prospective GOELAMS study. Blood 2012; 119: 29432948.
  • 11
    Boissel N,Renneville A,Biggio V, et al. Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. Blood 2005; 106: 36183620.
  • 12
    Kiyoi H,Naoe T,Yokota S, et al. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia 1997; 11: 14471452.
  • 13
    Ferrara F,Izzo T,Criscuolo C, et al. Favorable outcome in patients with acute myelogenous leukemia with the nucleophosmin gene mutation autografted after conditioning with high-dose continuous infusion of idarubicin and busulfan. Biol Blood Marrow Transplant 2010; 16: 10181024.
  • 14
    Gorin N-C,Labopin M,Frassoni F, et al. Identical outcome after autologous or allogeneic genoidentical hematopoietic stem-cell transplantation in first remission of acute myelocytic leukemia carrying inversion 16 or t(8;21): A retrospective study from the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol 2008; 26: 31833188.
  • 15
    Kuwatsuka Y,Miyamura K,Suzuki R, et al. Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes. Blood. 2009; 113: 20962103.
  • 16
    Zittoun RA,Mandelli F,Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 1995; 332: 217223.
  • 17
    Reiffers J,Stoppa AM,Attal M, et al. Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: The BGMT 87 study. Leukemia 1996; 10: 18741882.
  • 18
    Ravindranath Y,Yeager AM,Chang MN, et al. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group. N Engl J Med 1996; 334: 14281434.
  • 19
    Harousseau JL,Cahn JY,Pignon B, et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM). Blood 1997; 90: 29782786.
  • 20
    Burnett AK,Goldstone AH,Stevens RM, et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: Results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet 1998; 351: 700708.
  • 21
    Cassileth PA,Harrington DP,Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Eng J Med 1998; 339: 16491656.
  • 22
    Nathan PC,Sung L,Crump M, et al. Consolidation therapy with autologous bone marrow transplantation in adults with acute myeloid leukemia: A meta-analysis. J Natl Cancer Inst 2004; 96: 3845.
  • 23
    Levi I,Grotto I,Yerushalmi R, et al. Meta-analysis of autologous bone marrow transplantation versus chemotherapy in adult patients with acute myeloid leukemia in first remission. Leuk Res 2004; 28: 605612.
  • 24
    Henon PR,Liang H,Beck-Wirth G, et al. Comparison of hematopoietic and immune recovery after autologous bone marrow or blood stem cell transplants. Bone Marrow Transplant 1992; 9: 285291.
  • 25
    To LB,Roberts MM,Haylock DN, et al. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 1992; 9: 277284.
  • 26
    Martín C,Torres A,León A, et al. Autologous peripheral blood stem cell transplantation (PBSCT) mobilized with G-CSF in AML in first complete remission. Role of intensification therapy in outcome. Bone Marrow Transplant 1998; 21: 375382.
  • 27
    Michel G,Landman-Parker J,Auclerc MF, et al. Use of recombinant human granulocyte colony-stimulating factor to increase chemotherapy dose-intensity: A randomized trial in very high-risk childhood acute lymphoblastic leukemia. J Clin Oncol 2000; 18: 15171524.
  • 28
    Harousseau JL,Witz B,Lioure B, et al. Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: Results of a randomized trial of the Groupe Ouest-Est Leucémies Aigues Myeloblastiques. J Clin Oncol 2000; 18: 780787.